Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Meridian Bioscience, Inc.    VIVO

MERIDIAN BIOSCIENCE, INC. (VIVO)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Meridian Bioscience : Glancy Prongay & Murray Reminds Investors of the January 16, 2018 Deadline in the Class Action Lawsuit Against Meridian Bioscience, Inc. (VIVO)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/13/2018 | 03:36am CEST

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the January 16, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Meridian Bioscience, Inc. (“Meridian Bioscience” or the “Company”) (NASDAQ: VIVO) securities between March 25, 2016 and July 13, 2017, inclusive (the “Class Period”) Meridian Bioscience investors have until January 16, 2018 to file a lead plaintiff motion. To obtain information or participate in the class action, please visit the Meridian Bioscience page on our website at www.glancylaw.com/case/meridian-bioscience-inc.

Investors suffering losses on their Meridian Bioscience investments are encouraged to contact Lesley Portnoy of GPM to discuss their legal rights in this class action at 310-201-9150 or by email to [email protected].

On May 17, 2017, the U.S. Food and Drug Administration (“FDA”) issued a warning to Meridian that lead tests conducted by the Company’s subsidiary, Magellan Diagnostics, may be incorrect. According to the FDA, tests performed on blood drawn from a vein has led to “results that are lower than the actual level of lead in the blood.” The FDA has recommended discontinuation of Magellan when testing with venous blood samples. On this news, Meridian shares fell over 9% on May 17, 2017. Then on May 25, 2017, Meridian’s Magellan Diagnostics announced a Class 1 recall of its LeadCare Plus and Ultra Testing Systems due to “inaccurate test results.”

On June 6, 2017 Meridian’s Magellan Diagnostics subsidiary expanded the recall to incorporate the Company’s LeadCare and LeadCare II testing systems. On this news, shares of Meridian traded as low as $13.40 per share.

The complaint alleges that throughout the class period Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Defendant’s lead tests provide inaccurate results; and (2) consequently, Meridian’s public statements were materially false and misleading at all relevant times.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased shares of Meridian Bioscience during the Class Period you may move the Court no later than January 16, 2018 to ask the Court to appoint you as lead. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


© Business Wire 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERIDIAN BIOSCIENCE, INC.
06/28MERIDIAN BIOSCIENCE : Expects to Report Third Quarter Fiscal Year 2018 Operating..
AQ
05/31MERIDIAN BIOSCIENCE : Introduces Critical Raw Materials for Nipah Virus Diagnosi..
AQ
05/30Meridian Introduces Critical Raw Materials for Nipah Virus Diagnosis, a Key E..
GL
05/10MERIDIAN BIOSCIENCE : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIO..
AQ
05/04MERIDIAN BIOSCIENCE, INC. : Ex-dividend day for
FA
04/26MERIDIAN BIOSCIENCE : Fiscal 2Q Earnings Snapshot
AQ
04/26MERIDIAN BIOSCIENCE (NASDAQ : VIVO) reported earnings of $0.21 per share meeting..
AQ
04/26MERIDIAN BIOSCIENCE INC : Results of Operations and Financial Condition, Financi..
AQ
04/26Meridian Bioscience Reports Second Quarter 2018 Operating Results, Declares R..
GL
04/04Meridian Bioscience, Inc. Expects to Report Second Quarter Fiscal Year 2018 O..
GL
More news
News from SeekingAlpha
06/06Meridian Bioscience (VIVO) Presents At Jefferies 2018 Global Healthcare Confe.. 
05/24TOP WALL STREET HEALTHCARE GAINERS F : Allergan, CVS Health, Patterson, Sanofi, .. 
05/22Meridian Bioscience (VIVO) Presents At 2018 UBS Global Healthcare Conference .. 
04/26Meridian Bioscience declares $0.125 dividend 
04/26Meridian Bioscience EPS in-line, beats on revenue 
Financials ($)
Sales 2018 212 M
EBIT 2018 38,9 M
Net income 2018 25,6 M
Finance 2018 8,70 M
Yield 2018 3,16%
P/E ratio 2018 26,33
P/E ratio 2019 20,26
EV / Sales 2018 3,11x
EV / Sales 2019 2,95x
Capitalization 669 M
Chart MERIDIAN BIOSCIENCE, INC.
Duration : Period :
Meridian Bioscience, Inc. Technical Analysis Chart | VIVO | US5895841014 | 4-Traders
Technical analysis trends MERIDIAN BIOSCIENCE, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Average target price 14,0 $
Spread / Average Target -11%
EPS Revisions
Managers
NameTitle
John P. Kenny Chief Executive Officer & Director
John A. Kraeutler Executive Chairman
Lawrence J. Baldini Executive VP & President-Global Operations
Melissa A. Lueke CFO, Secretary, CAO, EVP & Head-Investor Relations
David C. Phillips Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERIDIAN BIOSCIENCE, INC.12.14%669
MEDTRONIC PLC8.64%119 342
BAXTER INTERNATIONAL15.64%40 201
ALIGN TECHNOLOGY66.76%29 698
ZIMMER BIOMET HOLDINGS-5.73%23 124
HOYA CORPORATION12.12%21 722